Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congress 2022
SEOUL, South Korea--(BUSINESS WIRE)--Genexine (KOSDAQ: 095700), a publicly traded, clinical-stage Korean biopharmaceutical company committed to the discovery and development of...

Sensex surges 1,600 points as oil slides after U.S. midterm results lift risk appetite
Doncic scores 40 as Lakers beat Kings 116-103 at Golden 1 Center
Xiaomi starts global HyperOS 4 rollout with Android 17; POCO F8 Pro in first wave
Chase wins toss, West Indies 69/3 on day one as WI look to seal series vs Bangladesh in Sylhet
PFC declares ₹4.10 second interim dividend as standalone Q2 PAT rises 11.76% 




























